Filing Analysis
CVRx, Inc. announced that CFO Jared Oasheim has resigned to pursue other professional opportunities. He will remain in his role until a successor is found, with a transition period extending into a consultancy role through February 2027.
🚩 Red Flags
- Departure of a key financial officer (CFO) can create instability in financial reporting and strategic planning for micro-cap companies.
📋 Key Facts
- Jared Oasheim gave notice of resignation on June 7, 2026.
- Oasheim will remain full-time until the later of August 31, 2026, or 30 days after a successor starts.
- A consulting arrangement is established through February 2027 at a rate of $245 per hour.
- The company will pay Oasheim a cash payment of $262,000 for transition/consulting commitments, split between November 30, 2026, and February 28, 2027.
- Oasheim is eligible for his full 2026 cash incentive payout regardless of termination date.
- The company is currently searching for a successor CFO.
CVRx, Inc. reported the voting results from its 2026 annual meeting of stockholders held on June 1, 2026. The stockholders elected three Class II directors and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the 2026 fiscal year.
📋 Key Facts
- Annual meeting held on June 1, 2026.
- Three Class II directors (Michael Dale, Kevin Hykes, and Joseph Slattery) were elected to serve until the 2029 annual meeting.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 2 (Auditor ratification) received 21,150,201 votes 'For' and 2,275,126 votes 'Against'.
CVRx, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a standard quarterly earnings disclosure under Item 2.02.
📋 Key Facts
- The report was filed on May 11, 2026, covering the fiscal quarter ended March 31, 2026.
- The financial results were disclosed through a press release attached as Exhibit 99.1.
- The information in the filing is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
- CVRx, Inc. is identified as an emerging growth company.
CVRx, Inc. announced preliminary Q1 2026 financial results featuring 20% year-over-year revenue growth and a significant improvement in gross margins to 87%. The company also reported the activation of the first clinical site for its BENEFIT-HF trial and improved reimbursement approval rates following a transition to Category I CPT codes.
🚩 Red Flags
- Operating expenses of $25 million continue to significantly exceed total revenue of $14.8 million, indicating ongoing net losses.
- The financial results are preliminary and unaudited, subject to final adjustments.
📋 Key Facts
- Preliminary Q1 2026 revenue expected between $14.7 million and $14.8 million, a 20% increase over Q1 2025.
- Gross margin improved to approximately 87% compared to 84% in the prior year period.
- Cash and cash equivalents totaled approximately $72.3 million as of March 31, 2026.
- Medicare Advantage 30-day approval rates for prior authorizations increased to 50% in early 2026, up from 31% in 2024.
- The BENEFIT-HF clinical trial activated its first site on March 31, 2026, with enrollment expected to begin in Q2 2026.
- U.S. active implanting centers increased to 257 from 252 at the end of 2025.
CVRx, Inc. granted incremental Performance Stock Units (PSUs) to its executive officers, tied to cumulative revenue targets for the 2026-2027 period. The awards are designed for retention and to incentivize achievement of near-term growth objectives, with final vesting occurring in late 2028.
📋 Key Facts
- Incremental PSU awards granted to all executive officers on February 27, 2026
- Awards are tied to a cumulative revenue goal for the fiscal 2026-2027 performance period
- Grant date value equals 75% of the officers' annual long-term incentives for fiscal 2026
- Vesting occurs 50% upon performance certification and 50% on December 31, 2028
- Payout ranges from 50% to 200% of target based on performance levels